Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
For decades, Melexis has run with very little or no debt. As of 2024, it has EUR 170 million in net debt, or 0.8 times its 2024 EBIT. We expect Melexis will distribute most of its free cash flow in ...